The effectiveness of trimebutin in the treatment of patients with irritable bowel syndrome: selected clinical cases
- Authors: Dicheva D.T1, Kunkina Y.B1
-
Affiliations:
- A.I. Yevdokimov Moscow State University of Medicine and Dentistry
- Issue: Vol 27, No 2 (2020)
- Pages: 100-104
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312530
- DOI: https://doi.org/10.18565/pharmateca.2020.2.100-104
- ID: 312530
Cite item
Open Access
Access granted
Abstract
Background. Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal tract (GIT), manifested by periodic abdominal pain associated with a change in the frequency of defecation and/or a change in the consistency of the stool. Currently, one of the most effective and safe drugs for the treatment of IBS is trimebutin, which from the modern point of view is considered not just as an antispasmodic, but as a means of regulating gastrointestinal motility. A series of clinical cases. The article presents clinical observations demonstrating objective difficulties associated with the management of IBS patients, including during pregnancy and in the presence of psycho-emotional stress, as well as the effectiveness of the use of trimebutin in these situations as a drug for the treatment and prevention. Conclusion. Clinical observations reviewed demonstrate objective difficulties associated with pharmacotherapy of patients with IBS. In the above cases, trimebutin is the optimal drug in terms of both effectiveness and safety. Thus, the use of trimebutin, which has a normokinetic effect on the motility of the lower gastrointestinal tract, as well as antispastic and analgesic effects, is considered a priority treatment strategy for patients suffering from IBS.
Keywords
Full Text
About the authors
D. T Dicheva
A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Email: di.di4eva@yandex.ru
Cand. Sci. (Med.), Associate Professor at the Department of Propaedeutics of Internal Diseases and Gastroenterology Moscow, Russia
Yu. B Kunkina
A.I. Yevdokimov Moscow State University of Medicine and DentistryMoscow, Russia
References
- Lacy B.E., Mearin F., Chang L., et al. Bowel Disorders. Gastroenterology. 2016;150:1393-1407. doi: 10.1053/j.gastro.2016.02.031.
- Андреев Д.Н., Заборовский А.В., Трухманов А.С. и др. Эволюция представлений о функциональных заболеваниях желудочно-кишечного тракта в свете Римских критериев IV пересмотра (2016). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;1:4-11.
- Halpert A. Irritable Bowel Syndrome: Patient-Provider Interaction and Patient Education. J Clin Med. 2018;7(1):pii: E3. Doi: 10.3390/ jcm7010003.
- Самсонов А.А., Андреев Д.Н., Дичева Д.Т. Синдром раздраженного кишечника с позиций современной гастроэнтерологии. Фарматека. 2014;18(291):7-14.
- Дичева Д.Т., Андреев Д.Н., Щегланова М.П., Парцваниа-Виноградова Е.В. Синдром раздраженного кишечника в свете римских критериев IV пересмотра (2016). Медицинский совет. 2018;3:60-6.
- Chang L., Lembo A., Sultan S. American Gastroenterological Association technical review on the pharmacological management of irritable bowel syndrome. Gastroenterology 2014;147:1149-72. doi: 10.1053/j.gastro.2014.09.002.
- Маев И.В., Самсонов А.А., Андреев Д.Н. Современный алгоритм ведения пациентов с синдромом хронического запора с позиций внедрения новых фармакологических препаратов. Фарматека. 2012;13:37-43.
- Андреев Д.Н., Дичева Д.Т. Современные немедикаментозные и фармакотерапевтические подходы к лечению синдрома раздраженного кишечника. Гастроэнтерология. Приложение к журналу Consilium Medicum. 2014;2:47-52.
- Андреев Д.Н., Дичева Д.Т. Оптимизация лечения пациентов с синдромом раздраженного кишечника: фокус на повышение комплаентности. Медицинский совет. 2019;3:118-24.
- Маев И.В., Черёмушкин С.В., Кучерявый Ю.А., Андреев Д.Н. Синдром раздраженного кишечника с позиций современной фундаментальной и клинической медицины. М., 2019
- Roman F.J., Lanet S., Hamon J., et al. Pharmacological properties of trimebutine and M-monodesmethyltrimebutine. J Pharmacol Exp Ther. 1999;289(3):1391-97.
- Delvaux M., Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res. 1997;25(5):225-46. doi: 10.1177/030006059702500501.
- Lee H.T., Kim B.J. Trimebutine as a modulator of gastrointestinal motility. Arch Pharm Res. 2011;34(6):861-64. doi: 10.1007/s12272- 011-0600-7.
- Nagasaki M., Kobayashi T., Tamaki H. Effects of trimebutine on cytosolic Ca2+ and force transitions in intestinal smooth muscle. Eur J Pharmacol. 1991;195:317-21. doi: 10.1016/0014-2999(91)90471-2.
- Morisawa T., Hasegawa J., Tanabe K., et al. Effects of trimebutine maleate on delayed rectifier K+ currents in guinea-pig ventricular myocytes. J Pharm Pharmacol. 2000;52:403-8. doi: 10.1211/0022357001774156.
- Nagasaki M., Komori S., Tamaki H.,Ohashi H. Effect of trimebutine on K+ current in rabbit ileal smooth muscle cells. Eur J Pharmacol. 1993;235:197-203. doi: 10.1016/0014-2999(93)90137-7.
- Poynard T., Regimbeau C., Benhamou Y. Metaanalysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15(3):355-61. doi: 10.1046/j.1365-2036.2001.00937.x.
- Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(5):76-93
Supplementary files
